lymphoma-evidence-entities

An oral drug blocking the enzymes EZH2 and EZH1 produced responses in 48 per cent of people with relapsed adult T-cell leukaemia/lymphoma, most of whom had already had mogamulizumab.

The study in which brentuximab vedotin made relapsed systemic anaplastic large cell lymphoma shrink in 86 per cent of patients and disappear on scans in 57 per cent.

An antibody-drug conjugate aimed at CD30 made the lymphoma shrink in 86 per cent of people with relapsed anaplastic large cell lymphoma, and disappear on scans in more than half.

A lung cancer drug that blocks ALK made relapsed ALK-positive lymphoma disappear on scans in most of the children who took it.

In advanced NK/T-cell lymphoma, a gentler regimen built on pegylated asparaginase kept the disease controlled for longer than SMILE, the regimen it was compared with, and caused fewer dangerously low white cell counts.

The interim report of the Chinese trial comparing two asparaginase regimens in advanced NK/T-cell lymphoma, on its first 42 patients.

The Japanese study in which the anti-CCR4 antibody mogamulizumab produced a response in half of people with relapsed adult T-cell leukaemia/lymphoma.

In a single-arm study of 53 people with MYC-rearranged aggressive B-cell lymphoma, including double-hit disease, intensive infusional chemotherapy left 71 per cent alive and free of events at four years.

Adding mogamulizumab to intensive chemotherapy for newly diagnosed adult T-cell leukaemia raised the complete remission rate from 33 to 52 per cent, with more side effects.

The final report of the Chinese randomised trial in which a pegaspargase regimen, DDGP, kept advanced NK/T-cell lymphoma controlled for longer than SMILE, with less toxicity to the blood count.

A tablet that blocks two enzymes controlling which genes are switched on shrank the disease in about half of people with relapsed adult T-cell leukaemia, nearly all of whom had already had mogamulizumab.

Six years after brentuximab vedotin for relapsed anaplastic large cell lymphoma, no one in the study had progressed after 40 months, and one in seven was still in remission with no further treatment of any kind.

Adding mogamulizumab to the intensive Japanese chemotherapy for newly diagnosed adult T-cell leukaemia raised the complete remission rate, at the cost of more side effects, including infections and lung inflammation.

An antibody against CCR4, a protein on the surface of most adult T-cell leukaemia cells, produced a response in half of the people in a Japanese study whose disease had come back after chemotherapy.

The randomised trial of mogamulizumab outside Japan, in which confirmed responses were seen in 11 per cent of people with relapsed adult T-cell leukaemia/lymphoma against none with chemotherapy.

A single-arm study gave an intensive infusional chemotherapy to people with aggressive B-cell lymphoma carrying a MYC rearrangement, including double-hit disease, and about seven in ten were alive and free of events four years later.

A PD-1 antibody given alone shrank the lymphoma in three out of four people whose NK/T-cell lymphoma had come back after asparaginase chemotherapy.

A Japanese study gave radiotherapy to the nose at the same time as a reduced-dose chemotherapy regimen, and three out of four people with early nasal NK/T-cell lymphoma were alive two years later, against fewer than half with radiotherapy alone in the past.

The report of the Chinese trial in which the PD-1 antibody sintilimab produced responses in 75 per cent of people whose NK/T-cell lymphoma had relapsed after asparaginase chemotherapy.

Outside Japan, mogamulizumab produced confirmed responses in about one in ten people with relapsed adult T-cell leukaemia, more than chemotherapy did but far fewer than the Japanese study had suggested.

Crizotinib produced responses in 83 to 90 per cent of children with relapsed ALK-positive anaplastic large cell lymphoma, most of them complete.